Literature DB >> 6216282

Allospecific human T cell lines and clones which mediate HLA-DR restricted helper activity.

S M Friedman, G S Thompson, M A Principato.   

Abstract

In order to analyze the immunoregulatory activity of allospecific human T cells, we have combined the techniques of limiting dilution culture and IL-2 dependent T cell growth to generate cloned alloreactive T cell lines (TCL). These TCL have been expanded in continuous culture for greater than 8 mo with retention of stable phenotypic and functional characteristics. For example, phenotypic analysis of alloproliferative TCL, utilizing a panel of monoclonal antibodies, demonstrate that these cultures are comprised of T cells belonging exclusively to the T3+ T4+ T8- "helper" or "inducer" T cell subset. Coculture of cloned alloproliferative TCL cells with a panel of allogeneic stimulators reveals that these clones are specifically reactive against the HLA-DRw1 determinant. Of greater interest, coculture of selected alloproliferative TCL cells with DRw1+ but not DRw1- B cells results in a vigorous polyclonal response as measured by the reverse hemolytic plaque assay. Although major histocompatibility complex restriction of this T-B interaction operates at the inductive level, help is at least partially unrestricted at the effector level as alloantigen-activated TCL cells provide demonstrable, although not maximal, help for DRw1- B cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6216282

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  PolyI.polyC12U-mediated inhibition of loss of alloantigen responsiveness viral replication in human CD4+ T cell clones exposed to human immunodeficiency virus in vitro.

Authors:  J Laurence; J Kulkosky; S M Friedman; D N Posnett; P O Ts'o
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

2.  Amplification of altered self-reactive cytolytic T lymphocyte responses by cloned, allospecific human Th cells.

Authors:  S M Friedman; A Green; C Russo; D N Posnett; D Diffley; M K Crow
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

3.  Biochemical basis of synergy between antigen and T-helper (Th) cell-mediated activation of resting human B cells.

Authors:  E K Chartash; M K Crow; S M Friedman
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

4.  Analysis of T-cell cultures and clones from a patient with classic rheumatoid arthritis--evidence for the existence of autoreactive T-cell clones in blood and synovial fluid.

Authors:  M Schlesier; C Ramb-Lindhauer; M Gärtner; H H Peter
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

5.  Differential requirements of B cells from normal and allergic subjects for the induction of IgE synthesis by an alloreactive T cell clone.

Authors:  D T Umetsu; D Y Leung; R Siraganian; H H Jabara; R S Geha
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

6.  Functionally restricted, allospecific, human helper T cell lines that amplify either B cell or cytolytic T cell responses.

Authors:  S M Friedman; G S Thompson
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

7.  Direct T helper-B cell interactions induce an early B cell activation antigen.

Authors:  M K Crow; J A Jover; S M Friedman
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

8.  Antigen-specific, MHC nonrestricted T helper cell-induced B cell activation.

Authors:  S M Friedman; J A Jover; E K Chartash; M K Crow
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

9.  A cloned major histocompatibility complex-restricted trinitrophenyl-reactive human helper T cell line that activates B cell subsets via two distinct pathways.

Authors:  M A Principato; G S Thompson; S M Friedman
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

10.  The same human alloreactive T cell clone can help both B lymphocytes and specific cytotoxic precursors.

Authors:  D Ramarli; B Parodi; M Fabbi; G Corte; A Lanzavecchia
Journal:  J Exp Med       Date:  1984-01-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.